Share price in low 5 range is basically the same as the price of 5 at the public offering from October 2007. I know there are more shares outstanding now, so the market cap is somewhat larger, but this does not reflect all the positive results since 2007:
1. FDA approved drug
2. Approval in several other countries
3. Deal and support of Pfizer
4. Validation of platform
5. New deal with Brazil and potentially all of Central and South America
6. Beginning sales in Israel with total tax break
7. Oral agent development with good initial results which could be ground-breaking
8. Chemical warfare use in Syria being a major topic of international discussion
9. New and improved facilities
10. 250 brilliant MDs and PhDs working diligently which is increased dramatically
11. Presumed advances in the "undisclosed proteins"
12. Significant time to forge new relationships
13. Global efforts to decrease health care costs
14. Pending better drug for Fabry using the same platform (40X greater half-life and possibly more efficacious with a 700 million to 1 billion dollar per year market)
15. Advances in Enbrel biosimilar. Could a different manufacturing process bypass the existing Amgen patent?
I'm sure I am leaving out some other advances. How does the market cap not increase? Another secondary done just before the FDA approval of Uplyso was also at a higher price than now. How?
I follow the company closely and still cannot determine the revenues from Uplyso in the US since approval on May 1st 2012 over a year ago.
I'm starting to agree with Nuselrami that the management of this company is getting richer and the shareholders languish. I continue to hold since I know the management wants the share price higher even more than I do to take advantage of their carefully crafted exit.
I hope management has something NEW to say at the meetings today and tomorrow. I could give the talk that I've heard Aviezer and company give over and over for years.